Marc Peter Bonaca MD
Non-Invasive Cardiology, Preventive Cardiology, Vascular Medicine
Instructor in Medicine, Brigham and Women's Hospital
Join to View Full Profile
13199 E Montview BlvdSuite 200Aurora, CO 80045
Dr. Bonaca is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Marc Bonaca is a cardiologist in Aurora, CO and is affiliated with multiple hospitals in the area, including Brigham and Women's Hospital and University of Colorado Hospital. He received his medical degree from University of Connecticut School of Medicine and has been in practice 14 years. He specializes in adult cardiology and vascular medicine and is experienced in peripheral vascular disease.
Education & Training
Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Vascular Medicine, 2010 - 2011
Harvard School of Public HealthMPH, Public Health, 2008 - 2011- Mass General Brigham/Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2006 - 2009
- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2003 - 2006
Uconn School Of MedicineClass of 2003
Certifications & Licensure
CO State Medical License 2019 - 2027
MA State Medical License 2005 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) Start of enrollment: 2007 Sep 01
- Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Start of enrollment: 2010 Oct 01
- Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events Start of enrollment: 2013 Apr 25
- Join now to see all
Publications & Presentations
PubMed
- Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-contr...Marc P Bonaca, Andrei-Mircea Catarig, Kim Houlind, Bernhard Ludvik, Joakim Nordanstig
Lancet. 2025-03-28 - 2 citationsAnticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials.Sina Rashedi, Mohammad Keykhaei, Alyssa Sato, Philippe Gabriel Steg, Gregory Piazza
Journal of the American College of Cardiology. 2025-03-25 - Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction - 2023 ESC recommendations and scientific evidence. Is cl...Jacek Kubica, Piotr Adamski, Jolita Badariene, Marc Bonaca, Piotr Buszman
Cardiology Journal. 2025-03-20
Journal Articles
- Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesNicholas A Marston, Marc P Bonaca, Petr Jarolim, Deepak L Bhatt, Stephen D Wiviott, Eugene Braunwald, Marc S Sabatine, JAMA Cardiology
- ASCVD Risk and Statin Use in PADMarc Bonaca, MD, JACC: Cardiovascular Imaging
- Rivaroxaban in Peripheral Artery Disease After RevascularizationMarc Bonaca, MD, The New England Journal of Medicine
- Join now to see all
Lectures
- Novel Approaches in Diabetic Patients After PCI: Role of SGLT2 Inhibitors and Potent Antiplatelet Therapy (THEMIS)CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019
- The Role of Antiplatelet Agents in Patients With Diabetes and Coronary DiseaseCRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019
- Highlights in Peripheral Artery Disease2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Join now to see all
Authored Content
- What Is Optimal Medical Therapy for CLTI? Can We Move the Needle with Drugs Alone?October 2020
- Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesAugust 2020
- ASCVD Risk and Statin Use in PADJuly 2020
- Rivaroxaban in Peripheral Artery Disease After RevascularizationMarch 2020
- Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients with Multivessel Coronary DiseaseJanuary 2018
- Reply Cost-Effectiveness of Long-Term Ticagrelor in Patients with Prior Myocardial Infarction: Analysis by SubgroupsJanuary 2018
- Join now to see all
Press Mentions
'I Shouldn't Need a Rosetta Stone to Understand Your Notes': What We Heard This WeekApril 6th, 2025- ACC: Semaglutide Beneficial in Patients with T2DM and Peripheral Artery DiseaseApril 3rd, 2025
- Semaglutide Shows Major Benefits in Peripheral Arterial Disease: STRIDEMarch 30th, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
